The Latest Breaking News from Benzinga

Robert Kiyosaki, best-selling author of "Rich Dad, Poor Dad," built a financial empire around one idea: the wealthy don't save money — they buy assets. While some see his market crash predictions as overblown, others hang on his every word, believing he sees the writing on the wall long before…

Wave Life Sciences Ltd. (NASDAQ:WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for obesity.

Marvell Technology, Inc. (NASDAQ:MRVL) shares are trading lower Monday after Benchmark downgraded the stock from a Buy rating to a Hold rating.

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).

The investment world loves to complicate simple truths. Wall Street will sell you exotic strategies, complex derivatives, and algorithmic trading systems that require three PhD mathematicians to understand.

Germany is on course for the highest corporate insolvency count in more than a decade, raising fresh questions about the resilience of the nation’s largest listed companies — and the ETFs that track them.

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.

Lululemon Athletica Inc. (NASDAQ:LULU) heads into its third-quarter report with slowing sales growth, a sharp margin squeeze from tariffs and weaker U.S. demand, as investors watch whether a major product “newness” push can reignite momentum, but likely not before 2026.

U.S. stocks were lower, with the Dow Jones falling more than 200 points on Monday.